Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
4 days agoNavan and MapLight Lead Post-Shutdown US IPO Revival with Nearly $1.2 B Raised
Corporate travel platform Navan and biotech firm MapLight Therapeutics spearheaded the rebound of US IPOs after the October government shutdown. Navan priced its debut at $27 per share, raising $923 million at an $8.1 billion valuation, while MapLight secured $251 million at $17 per share. Both listings were oversubscribed, marking renewed investor appetite in tech and biotech. The Nasdaq IPO Index climbed 4.2 percent post-launch, outperforming the S&P 500. Analysts said strong pricing momentum signals investor rotation back into growth sectors as monetary-policy uncertainty subsides.
positive
4 days agoNavan and MapLight Lead Post-Shutdown US IPO Revival with Nearly $1.2 B Raised
Corporate travel platform Navan and biotech firm MapLight Therapeutics spearheaded the rebound of US IPOs after the October government shutdown. Navan priced its debut at $27 per share, raising $923 million at an $8.1 billion valuation, while MapLight secured $251 million at $17 per share. Both listings were oversubscribed, marking renewed investor appetite in tech and biotech. The Nasdaq IPO Index climbed 4.2 percent post-launch, outperforming the S&P 500. Analysts said strong pricing momentum signals investor rotation back into growth sectors as monetary-policy uncertainty subsides.
positive
Navan and MapLight Lead Post-Shutdown US IPO Revival with Nearly $1.2 B Raised
4 days ago
1 min read
85 words
Navan and MapLight Therapeutics raised $1.17 B combined in IPO debuts, signaling revived US listing activity and improving risk appetite after the shutdown.
Corporate travel platform Navan and biotech firm MapLight Therapeutics spearheaded the rebound of US IPOs after the October government shutdown. Navan priced its debut at $27 per share, raising $923 million at an $8.1 billion valuation, while MapLight secured $251 million at $17 per share. Both listings were oversubscribed, marking renewed investor appetite in tech and biotech. The Nasdaq IPO Index climbed 4.2 percent post-launch, outperforming the S&P 500. Analysts said strong pricing momentum signals investor rotation back into growth sectors as monetary-policy uncertainty subsides.
Corporate travel platform Navan and biotech firm MapLight Therapeutics spearheaded the rebound of US IPOs after the October government shutdown. Navan priced its debut at $27 per share, raising $923 million at an $8.1 billion valuation, while MapLight secured $251 million at $17 per share. Both listings were oversubscribed, marking renewed investor appetite in tech and biotech. The Nasdaq IPO Index climbed 4.2 percent post-launch, outperforming the S&P 500. Analysts said strong pricing momentum signals investor rotation back into growth sectors as monetary-policy uncertainty subsides.
Companies:
Navan
MapLight Therapeutics
Tags:
ipo
startups
ipo
startups
us
biotech
tech
Oct 27, 2025 • 17:28 IST